Survey Reinforces the Effectiveness of Anti-TNF-Alpha to Treat Pediatric CD

Survey Reinforces the Effectiveness of Anti-TNF-Alpha to Treat Pediatric CD
Anti-tumor necrosis factor-α (TNF-Alpha) has been further established as an effective treatment for children who suffer from Crohn's disease (CD), as evaluated by a recent multi-institute survey. The results were published in the journal Pediatrics, compiling the collection of data from the ImproveCareNow (ICN) program, led by Christopher B. Forrest, MD, PhD, from the Department of Pediatrics at the Children's Hospital of Philadelphia, Pennsylvania. The ICN program consists of a compilation of physicians' opinions, data, and results about the treatment of CD. It included information on patients with moderate to severe CD, assessed at 10 to 16 weeks, collected from April 2007 to March 2012. The positive results may now offer additional assurance for physicians who are still reluctant to prescribe the expensive biologic to children. The survey demonstrated that anti-TNF-Alpha therapy was able to achieve clinical and corticosteroid-free remission, since the rate rations were 1.53 for clinical remission and 1.74 for corticosteroid-free remission, during the 26-week period after the treatment. The data confirmed the conclusions reached during the REACH trial, a multicenter, randomized, open-label, controlled trial performed with pediatric patients, as well as the SONIC trial, performed with adults. "Like an open-labeled randomized trial, the effect of treatment initiation in our nonrandomized trials tests the combination of pharmacological and behavioral effects induced by treatment awareness among clinicians and participants," explained the study authors. "Both patients and clinicians were aware of the decision to use biologic therapy. For this reason, we preferred the use of the sPCDAI [Short Pediatric Crohn's Disease Activity Index] over the Physician Glo
Subscribe or to access all post and page content.